Valuation: SCYNEXIS, Inc.

Market Cap 50.94M 45.27M 42.18M 38.47M 72.59M 4.91B 73.27M 511M 198M 2.5B 191M 187M 8.03B P/E 2026 *
-1.76x
P/E 2027 * -2.21x
Enterprise Value 50.94M 45.27M 42.18M 38.47M 72.59M 4.91B 73.27M 511M 198M 2.5B 191M 187M 8.03B EV / Sales 2026 *
82.2x
EV / Sales 2027 * 7.63x
Free-Float
98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day-4.66%
1 week+16.63%
Current month+3.64%
1 month-3.40%
3 months+15.58%
6 months-27.92%
Current year+1.20%
1 week 4.52
Extreme 4.5201
5.51
1 month 4.08
Extreme 4.08
5.51
Current year 3.53
Extreme 3.53
9.12
1 year 3.53
Extreme 3.53
9.12
3 years 3.53
Extreme 3.53
24.56
5 years 3.53
Extreme 3.53
64.8
10 years 3.53
Extreme 3.53
440.8
Manager TitleAgeSince
Chief Executive Officer 61 31/12/2022
Director of Finance/CFO 50 08/09/2026
Chief Tech/Sci/R&D Officer - 13/09/2026
Director TitleAgeSince
Director/Board Member 73 30/11/2008
Chairman 67 03/06/2015
Director/Board Member 61 31/12/2022
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Free

Director

11,500 0.1156%
09/09/26 Free

Chief Financial Officer

100,000 1.0051%
01/04/26 Buy

Chief Executive Officer

217,390 0.2736%
Change 5-day change 1-year change 3-year change Capi.($)
-4.66%+16.63%-20.00%-71.17% 50.94M
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -1.15%-1.39%+21.46%+44.89% 369.72B
Weighted average by Cap. -0.60%-3.33%+29.07%+69.98%

Financials

2026 *2027 *
Net sales 620K 551K 513K 468K 883K 59.66M 891K 6.22M 2.41M 30.4M 2.33M 2.28M 97.69M 6.68M 5.93M 5.53M 5.04M 9.51M 643M 9.6M 66.99M 25.98M 328M 25.07M 24.52M 1.05B
Net income -30.55M -27.15M -25.29M -23.07M -43.53M -2.94B -43.94M -306M -119M -1.5B -115M -112M -4.82B -32.43M -28.82M -26.85M -24.49M -46.21M -3.12B -46.65M -325M -126M -1.59B -122M -119M -5.11B
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
02/10/26 US$5.120 -4.66% 132,401
01/10/26 US$5.370 +8.70% 601,965
30/09/26 US$4.940 +6.01% 311,609
29/09/26 US$4.660 +0.87% 542,385
28/09/26 US$4.620 +5.24% 7,784,229
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.120USD
Average target price
36.33USD
Spread / Average Target
+609.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock